Therapeutic drug monitoring-guided SSRI dosing for hospitalized teens and adults
Official title: Therapeutic Drug Monitoring-Guided Treatment With Sertraline, or Escitalopram in Hospitalized Adults and Children
Run by Poznan University of Medical Sciences · NCT07478796 · Data updated 2026-11-12
This project will test whether using blood-level monitoring (TDM) to guide dosing of fluoxetine, escitalopram, or sertraline helps hospitalized patients aged 12 and older with moderate to severe depression.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 12 Years and up |
| Sex | All |
| Enrollment | 180 (estimated) |
| Sponsor | Poznan University of Medical Sciences Academic / other |
| Locations | 1 site (Poznan, Greater Poland Voivodeship) |
| Status | Recruiting |
| Started | April 3, 2025 |
| Main results expected | November 30, 2027 |
| Study ends | November 30, 2027 |
| Registry record updated | March 18, 2026 |
| Trial ID | NCT07478796 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are hospitalized patients aged 12 or older with a moderate to severe depressive episode who require SSRI treatment and can provide informed consent (with guardian consent as needed).
✕Probably not a fit
People with other primary psychiatric disorders (such as bipolar disorder or schizophrenia), active pregnancy or breastfeeding, unstable severe medical conditions, or those already on an adequate SSRI dose are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, head-to-head trial compares fluoxetine, escitalopram, and sertraline in patients aged 12 and older using prospective therapeutic drug monitoring (TDM) across all arms. The protocol includes dense plasma sampling, pharmacogenetic profiling, and population PK/PD model development to characterize exposure-efficacy and exposure-safety relationships. Primary aims are to derive model-based therapeutic concentration ranges and practical individualized dosing recommendations; secondary analyses will compare effectiveness, tolerability, and time-to-response among the three agents. The study is conducted at Poznan University of Medical Sciences and focuses on hospitalized youth and young adults with moderate to severe depressive episodes.
Why it matters
Potential benefit: If successful, this could provide practical individualized dosing ranges and TDM guidance to improve SSRI effectiveness and reduce side effects in adolescents and young adults.
How similar studies have gone: Previous TDM and PK/PD studies in adults have suggested exposure-response relationships for some SSRIs, but randomized, pediatric-focused head-to-head trials that combine dense sampling and pharmacogenetics are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female gender. * Age 12 years or older. * Diagnosis of moderate or severe depressive episode requiring SSRI treatment (fluoxetine, escitalopram, or sertraline). * Written informed consent provided by patient and/or legal guardian. * Women of childbearing potential must agree to use effective contraception or sexual abstinence. Exclusion Criteria: * Pregnancy, breastfeeding, or planning pregnancy. * Diagnosis of other mental disorders (schizophrenia, bipolar disorder, intellectual disability). * Decompensated severe somatic disorders (e.g., endocrine disorders, asthma exacerbation, hepatic/renal failure). * Treatment with fluoxetine, sertraline, or escitalopram at an adequate dose for at least 4 weeks for the current episode (unless washout of 5x half-life is observed). * Use of medications with high risk of CYP enzyme interactions.
Where it's running
-
Szpital Kliniczny im. Karola Jonschera UMP (Poznan University of Medical Sciences)
Poznan, Greater Poland Voivodeship, Poland Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Step-by-step care plan to improve treatment for moderate depression in general practice
It tests whether a structured step-by-step care plan used by general practitioners works better than usual GP care or psychologist-led behavioral therapy for adults 18–65 with moderate depression.
-
Understanding how the orbitofrontal cortex guides approach vs. avoidance in depression
This study tests how different parts of the orbitofrontal cortex influence whether people pursue rewards or risk loss, and whether this pattern is altered in Major Depressive Disorder.
-
Health education program to help depression in older adults and caregivers in Ho Chi Minh City
A community-based education program for people 60+ and their caregivers is being tested to see if it can lower depression and improve quality of life compared with standard care.
-
Prucalopride for low mood: testing a 5-HT4 receptor activator for cognition and sleep
This study tests whether prucalopride, a 5-HT4 receptor drug, can improve thinking and sleep in adults with low mood or major depressive disorder compared to a placebo.
-
Pre-visit Companion Brief: a primary care AI-assisted check for depression and anxiety
This pilot tests an AI-powered pre-visit assessment that creates a concise Companion Brief for clinicians to help identify depression and anxiety during routine primary care.
-
Medically tailored groceries to help depression in people with food insecurity
This trial tests whether giving medically tailored groceries for six months can reduce depressive symptoms in adults who have depression and struggle with access to food.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.